Suppr超能文献

通过中成药预防超重/肥胖成年人糖尿病:一项前瞻性队列研究的研究方案

Prevention of Diabetes in Overweight/Obese Adults through Traditional Chinese Patent Medicine: Study Protocol for a Prospective Cohort Study.

作者信息

Pang Bing, Zhang Yue-Ying, Hu Hua-Jie, Sun Ye, Cao Ai-Mei, Lu Chun-Qian, Zhang Wei-Hua, Ni Qing

机构信息

Department of Endocrinology, Guang' Anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.

Department of Endocrinology, Beijing Shunyi District Hospital of Chinese Medicine, Beijing, China.

出版信息

Evid Based Complement Alternat Med. 2021 Nov 8;2021:6006802. doi: 10.1155/2021/6006802. eCollection 2021.

Abstract

. Early intervention in prediabetes can prevent or delay the incidence of type 2 diabetes mellitus (T2DM). Traditional Chinese patent medicine (TCPM) is widely used in China to prevent T2DM. This study aims to evaluate the efficacy and safety of TCPMs for preventing T2DM. . This study is a multicenter, cohort study with two arms. A total of 600 participants will be recruited. The participants will be divided into either intervention or control groups according to their own desire, and the exposure factor is the application of TCPMs. All participants will be encouraged to lead a healthy lifestyle, and the intervention group also used TCPMs based on syndrome differentiation. Incident diabetes and normalization of blood glucose are indexes of end point. Safety assessments and adverse event monitoring will also be conducted. The treatment duration is set for 24 weeks, and we will follow-up for another 2 years. . This trial may provide initial evidence regarding the efficacy and safety of TCPMs plus lifestyle intervention (LI) compared to LI alone for preventing T2DM and provide a comprehensive intervention plans that choose suitable TCPMs for diabetes prevention according to syndrome differentiation. Chinese Clinical Trial Registry ID: ChiCTR1900023541, registered on 1 Jun 2019. The version identifier is 2018121702.

摘要

. 糖尿病前期的早期干预可预防或延缓2型糖尿病(T2DM)的发生。中药成药在中国被广泛用于预防T2DM。本研究旨在评估中药成药预防T2DM的疗效和安全性。. 本研究是一项双臂多中心队列研究。共招募600名参与者。参与者将根据自身意愿分为干预组或对照组,暴露因素为中药成药的应用。鼓励所有参与者保持健康的生活方式,干预组还根据辨证使用中药成药。新发糖尿病和血糖正常化是终点指标。还将进行安全性评估和不良事件监测。治疗持续时间设定为24周,我们还将进行另外2年的随访。. 本试验可能为中药成药联合生活方式干预(LI)与单纯LI预防T2DM的疗效和安全性提供初步证据,并提供根据辨证选择合适的中药成药进行糖尿病预防的综合干预方案。中国临床试验注册中心编号:ChiCTR1900023541,于2019年6月1日注册。版本标识符为2018121702。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acb9/8592719/a98c6a26bc2c/ECAM2021-6006802.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验